Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.34 |
| ▸ | CTRC | Q99895 | 5/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.32 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962022 | 0.93 | PYGL (0.37) | CMA1CTRCPYGLPSEN1PSEN2 | |
| SCHEMBL19969320 | 0.93 | PYGL (0.37) | CMA1CTRCPYGLPSEN1PSEN2 | |
| SCHEMBL19962092 | 0.84 | OXTR (0.36) | CMA1PYGLOXTR | |
| SCHEMBL19962078 | 0.82 | OXTR (0.41) | PYGLOXTR | |
| SCHEMBL19969150 | 0.82 | OXTR (0.41) | PYGLOXTR | |
| SCHEMBL19962061 | 0.81 | PYGL (0.34) | CMA1CTRCPYGLPSEN1PSEN2 | |
| SCHEMBL19962095 | 0.81 | PYGL (0.37) | CMA1CTRCPYGLPSEN1PSEN2 | |
| SCHEMBL19969222 | 0.81 | PYGL (0.37) | CMA1CTRCPYGLPSEN1PSEN2 | |
| SCHEMBL19969188 | 0.79 | PYGL (0.36) | PYGLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19962083 | 0.79 | PYGL (0.36) | PYGLPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | CMA1 2432/4885CTRC 3599/4885PYGL 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.